Metreleptin for treating lipodystrophy (HST14)
Evidence-based recommendations on metreleptin (Myalepta) for treating lipodystrophy in children and adults
Search results
43 results
-
-
Leukomed Sorbact for preventing surgical site infection (MTG55)
Evidence-based recommendations on Leukomed Sorbact for preventing surgical site infection after caesarean section or vascular surgery
-
The VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal (MTG54)
Evidence-based recommendations on the VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal
-
The PLASMA system for transurethral resection and haemostasis of the prostate (MTG53)
Evidence-based recommendations on the PLASMA system for transurethral resection and haemostasis of the prostate
-
Zio XT for detecting cardiac arrhythmias (MTG52)
Evidence-based recommendations on Zio XT for detecting cardiac arrhythmias
-
Volanesorsen for treating familial chylomicronaemia syndrome (HST13)
Evidence-based recommendations on volanesorsen (Waylivra) for treating familial chylomicronaemia syndrome in adults
-
SEM Scanner 200 for preventing pressure ulcers (MTG51)
Evidence-based recommendations on SEM Scanner 200 for preventing pressure ulcers
-
Behaviour change: digital and mobile health interventions (NG183)
This guideline covers interventions that use a digital or mobile platform to help people eat more healthily, become more active, stop smoking, reduce their alcohol intake or practise safer sex. The interventions include those delivered by text message, apps, wearable devices or the internet. The guideline only includes those that are delivered by the technology itself and not by healthcare professionals using technology to deliver interventions.
-
Axonics sacral neuromodulation system for treating refractory overactive bladder (MTG50)
Evidence-based recommendations on Axonics sacral neuromodulation system for treating refractory overactive bladder
-
Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (MTG49)
Evidence-based recommendations on Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia
-
PneuX to prevent ventilator-associated pneumonia (MTG48)
Evidence-based recommendations on PneuX to prevent ventilator-associated pneumonia
-
Episcissors-60 for mediolateral episiotomy (MTG47)
Evidence-based recommendations on Episcissors-60 for mediolateral episiotomy
-
Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C (MTG27)
Evidence-based recommendations on Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C
-
Indoor air quality at home (NG149)
This guideline covers indoor air quality in residential buildings. It aims to raise awareness of the importance of good air quality in people's homes and how to achieve this.
-
gammaCore for cluster headache (MTG46)
Evidence-based recommendations on gammaCore for cluster headache
-
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children
-
Workplace health: long-term sickness absence and capability to work (NG146)
This guideline covers how to help people return to work after long-term sickness absence, reduce recurring sickness absence, and help prevent people moving from short-term to long-term sickness absence.
-
Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)
Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherit
-
EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing (MTG12)
Evidence-based recommendations on EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing
-
Tegaderm CHG securement dressing for vascular access sites in critically ill adults (MTG25)
Evidence-based recommendations on The 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites
-
Patisiran for treating hereditary transthyretin amyloidosis (HST10)
Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy
-
Alcohol interventions in secondary and further education (NG135)
This guideline covers interventions in secondary and further education to prevent and reduce alcohol use among children and young people aged 11 up to and including 18. It also covers people aged 11 to 25 with special educational needs or disabilities in full-time education. It will also be relevant to children aged 11 in year 6 of primary school.
-
PICO negative pressure wound dressings for closed surgical incisions (MTG43)
Evidence-based recommendations on PICO negative pressure wound dressings for closed surgical incisions
-
Ambu aScope4 Broncho for use in unexpected difficult airways (MTG14)
Evidence-based recommendations on the Ambu aScope4 Broncho for use in unexpected difficult airways
-
Endocuff Vision for assisting visualisation during colonoscopy (MTG45)
Evidence-based decisions on Endocuff Vision for assisting visualisation during colonoscopy
-
The Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters (MTG24)
Evidence-based recommendations on The Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters
-
Inotersen for treating hereditary transthyretin amyloidosis (HST9)
Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis
-
Curos for preventing infections when using needleless connectors (MTG44)
Evidence-based recommendations on Curos for preventing infections when using needleless connectors
-
The Debrisoft monofilament debridement pad for use in acute or chronic wounds (MTG17)
Evidence-based recommendations on the Debrisoft monofilament debridement pad for use in acute or chronic wounds
-
UrgoStart for treating diabetic foot ulcers and leg ulcers (MTG42)
Evidence-based recommendations on UrgoStart for treating diabetic foot ulcers and leg ulcers
-
Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain (MTG41)
Evidence-based recommendations on the Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain
-
Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers (MTG40)
Evidence-based recommendations on Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers
-
Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms (MTG10)
Evidence-based recommendations on the Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms
-
Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia (XLH) in children and young people
-
iFuse for treating chronic sacroiliac joint pain (MTG39)
Evidence-based recommendations on iFuse for treating chronic sacroiliac joint pain
-
E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta (MTG16)
Evidence-based recommendations on the E-vita open plus for treating complex aneurysms and dissections of the thoracic aorta
-
Neuropad for detecting preclinical diabetic peripheral neuropathy (MTG38)
Evidence-based recommendations on Neuropad for detecting preclinical diabetic peripheral neuropathy
-
Preventing suicide in community and custodial settings (NG105)
This guideline covers ways to reduce suicide and help people bereaved or affected by suicides. It aims to:
-
Flu vaccination: increasing uptake (NG103)
This guideline covers how to increase uptake of the free flu vaccination among people who are eligible. It describes ways to increase awareness and how to use all opportunities in primary and secondary care to identify people who should be encouraged to have the vaccination.
-
Community pharmacies: promoting health and wellbeing (NG102)
This guideline covers how community pharmacies can help maintain and improve people’s physical and mental health and wellbeing, including people with a long-term condition. It aims to encourage more people to use community pharmacies by integrating them within existing health and care pathways and ensuring they offer standard services and a consistent approach. It requires a collaborative approach from individual pharmacies and their representatives, local authorities and other commissioners.
-
Stop smoking interventions and services (NG92)
This guideline covers stop smoking interventions and services delivered in primary care and community settings for everyone over the age of 12. It aims to ensure that everyone who smokes is advised and encouraged to stop and given the support they need. It emphasises the importance of targeting vulnerable groups who find smoking cessation hard or who smoke a lot.
-
Physical activity and the environment (NG90)
This guideline covers how to improve the physical environment to encourage and support physical activity. The aim is to increase the general population’s physical activity levels.
-
Thopaz+ portable digital system for managing chest drains (MTG37)
Evidence-based recommendations on Thopaz+ for managing chest drains